The High-performance Liquid Chromatography (HPLC) Market is projected to reach $7.9 billion by 2030, at a CAGR of 5.2% from 2023 to 2030. High-performance liquid chromatography (HPLC) is the chromatographic process of dividing the ingredients in a mixture to purify, identify, and quantify components. HPLC has been used in multiple applications, including developing and manufacturing pharmaceutical and biological products, separating components of a complex biological sample in analytical chemistry, and detecting vitamin D levels in blood serum in clinical diagnostics.
The HPLC market covers HPLC systems, consumables, components & accessories, and software & services offered by key companies for clinical research, diagnostics, forensics and other applications for use in pharmaceutical & biopharmaceutical industries, research & academic institutes, and food & beverage industries.
Increasing R&D investments in the pharmaceutical and biotechnology industries, technological advancements in HPLC, rising food safety concerns, and stringent policies and initiatives to reduce environmental pollution drive the market’s growth. However, the high cost of HPLC instruments restrains this market's growth.
Emerging economies and the development of bio-clusters to foster research offer opportunities for market growth. However, the shortage of skilled HPLC professionals and the adoption of refurbished HPLC instruments are the major challenges to market growth.
Strong R&D Pipeline for Biopharmaceuticals to Drive the Demand for HPLC Market
At present, antibody-based biopharmaceuticals are dominating the market. There is a large number of antibody-based biopharmaceuticals present in the clinical pipeline of various biopharmaceutical companies. According to the data released by the Antibody Society, an international non-profit antibody-related research and development organization, as of January 10, 2021, 21 investigational antibody therapeutics were under regulatory review in the U.S. and European Union. With more biopharmaceuticals entering a commercial stage, the demand for bioprocessing equipment and consumables used in their production is expected to grow.
As per the U.S. FDA, 30 biosimilars have received regulatory approvals, and 21 products have been launched as of January 2022. Biosimilars usually range from 15% to 37% lower than reference products and have increased the competition. Additionally, according to Sandoz International GmbH (Germany), in the U.S., in 2021, biosimilars generated USD 7 billion in savings for patients and the healthcare system.
Capacity Expansions of Biopharmaceutical Plants to Propel the Demand for HPLC Systems
Biosimilars are gaining significant importance in oncology, autoimmune diseases, and rare diseases. The price advantage of biosimilars compared to biologics and the biosimilar substitution laws is boosting the demand for biosimilars. Several manufacturers are expanding their manufacturing facilities to meet the growing demand for biopharmaceuticals. The COVID-19 pandemic also resulted in the facility expansion of vaccine manufacturing plants. These capacity expansions from biopharmaceutical manufacturers and CDMOs will generate additional demand for biopharmaceutical manufacturing equipment and consumables, propelling the market’s growth. For instance, in December 2021, Biocon Ltd. (India) and Mylan N.V. (U.S.) announced their plans to combine their biosimilar businesses to create a larger company.
-Market.webp "High-performance Liquid Chromatography (HPLC) Market")
Click here to: Get Free Sample Pages of this Report
Key Findings in the High-performance Liquid Chromatography Market Study
In 2023, the HPLC Systems Segment is Expected to Account for the Largest Share of the High-performance Liquid Chromatography Market
Among the products, in 2023, the HPLC systems segment is expected to account for the largest share of the HPLC market. The large market share of this segment is attributed to the availability of integrated and modular systems that can be used for various applications. Modular HPLC systems are stacked according to the need of the customers. Hence they are widely adopted for budget-constraint end users. Integrated systems have in-built modules that are preferred for applications requiring continuous analysis of samples.
In 2023, the Pharmaceutical & Biopharmaceutical Industries Segment Expected to Account for the Largest Share of the High-performance Liquid Chromatography Market
Among the end users, in 2023, the pharmaceutical & biopharmaceutical industries segment is expected to account for the largest share of the HPLC market. The large market share of this segment is attributed to the rise in the number of drugs in clinical studies, the high prevalence of infectious and non-infectious diseases, growing pressure on pharmaceutical companies to launch new therapies in the market, and the increasing investments in biopharmaceuticals.
North America to Dominate the Market in 2023
In 2023, North America is expected to account for the largest share of the global HPLC market. North America’s major market share is attributed to rising investments in pharmaceutical R&D, increased sales of pharmaceuticals, stringent environmental policies for monitoring pesticide & industrial chemical degrades, well-developed research infrastructure, and the presence of key market players in the region. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2021, North America accounted for 49.1% of global pharmaceutical sales.
Key Players
This report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market participants in the last few years. The key players profiled in the HPLC market report are Waters Corporation (U.S.), Shimadzu Corporation (Japan), Danaher Corporation (U.S.), Bruker Corporation (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Sartorius AG (Germany), Gilson, Inc. (U.S.), Tosoh Corporation (Japan), Hitachi, Ltd. (Japan), and JASCO Corporation (Japan).
Scope of the Report:
High-performance Liquid Chromatography Market Assessment, by Product
- HPLC Systems
- Consumables
- Columns
- Pre-packed Columns
- Empty Columns
- Reagents & Buffers
- Vials
- Fittings & Tubing
- Syringe Filters
- Well Plates
- Other Consumables
- Components & Accessories
- Detectors & Lamps
- Pumps
- Fraction Collectors
- Other Components & Accessories
- Software & Services
(Notes: 1. Other consumables include ferrules, fused silica adapters, seals, caps, septa, and membranes.
2. Other components & accessories include injectors, degassers, column ovens, mixers, plungers, reducers,
valves, adapters, connectors, injection needles, valve seals, frits, plungers, and cartridges.)
High-performance Liquid Chromatography Market Assessment, by End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Food & Beverage Companies
- Environmental Testing Laboratories
- Hospitals & Clinics
- Oil & Gas Industries
- Other End Users
(Note: Other end users include forensic laboratories and chemical and cosmetic industries.)
High-performance Liquid Chromatography Market Assessment, by Geography
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Key questions answered in the report:
